Differentiated In Vitro Efficacy of BYL719, ARQ092, and Rapamycin on Fibroblasts Isolated From a Chinese PIK3CA-Related Overgrowth Spectrum Individual With a Novel Variant
Fei Xiong, Qian Wang, Shi-Qi Wang, Miao Zheng, Hai-Yan Zhong, Ming-Li Zou, Si-Ming Yuan
Journal：AMERICAN JOURNAL OF MEDICAL GENETICS PART A
IF：1.7
DOI：10.1002/ajmg.a.70099
PMID：
Published：2026-02-22
research field：分子生物学精准医学药理学细胞生物学遗传学
Abstract
Postzygotic mutations of the PIK3CA gene constitutively activate the PI3K/AKT/mTOR pathway in patients with PIK3CA -related overgrowth spectrum (PROS), causing congenital mosaic tissue overgrowth. We established primary fibroblast cells from a patient with a novel somatic frameshift mutation (c.3190_3191insA, [p.H1065fs]) in PIK3CA , in which PI3K/AKT/mTOR signaling is activated compared to control fibroblasts. We assessed the therapeutic effects of three compounds (BYL719, ARQ092, and rapamycin) on the PI3K/AKT/mTOR signaling pathway and cell growth. Notably, BYL719 is more effective at inhibiting the overactivation of all key signaling molecules in the pathway at lower concentrations in patient-derived fibroblasts, while showing no significant effect on control fibroblasts. The insertion frameshift mutation is not located within the five domains, but it is a gain-of-function PIK3CA mutation contributing to PROS development. The results further confirmed the obvious advantages of the compound in targeted therapy for PROS patients.
本文使用的Yeasen产品
